SPATA17

Across TCGA pan-cancer cohorts, SPATA17 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SPATA17 data layer compared with 22 for mass-spec protein.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher SPATA17 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SPATA17 expression acts as an unfavorable survival marker.

COAD, LUAD, and UCEC are the cancer types where SPATA17 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	OS	Median	III,IV	0.157	0.791	.001	18	view →
LUAD	OS	Median	All	0.544	0.814	.002	10	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	DFS	Median	IV	0.040	0.454	.028	6	view →
LGG	OS	Median	All	0.317	0.799	.015	3	view →
LIHC	DFS	Median	II,III,IV	0.080	0.414	.027	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SPATA17–COAD (OS)

Open the COAD breakdown →